# Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers

> **NCT03515551** · PHASE1,PHASE2 · TERMINATED · sponsor: **Immunocore Ltd** · enrollment: 29 (actual)

## Conditions studied

- Select Advanced Solid Tumors

## Interventions

- **DRUG:** IMCnyeso

## Key facts

- **NCT ID:** NCT03515551
- **Lead sponsor:** Immunocore Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-06-15
- **Primary completion:** 2021-05-10
- **Final completion:** 2021-05-10
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Strategic decision to stop development and not based on any safety concerns
- **Last updated:** 2022-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515551, "Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03515551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*